Screening of Big Pharma's Library against Various

Damijan Knez, Stanislav Gobec, Martina Hrast

Open access · goldAbstract read

In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.2field-weighted citation impact, top 51% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Damijan KnezFaculty of Pharmacy, University of Ljubljana, Aškerčeva 7, SI 1000 Ljubljana, Slovenia.ORCID 0000-0001-9917-1384

Stanislav GobecFaculty of Pharmacy, University of Ljubljana, Aškerčeva 7, SI 1000 Ljubljana, Slovenia.ORCID 0000-0002-9678-3083

Martina HrastFaculty of Pharmacy, University of Ljubljana, Aškerčeva 7, SI 1000 Ljubljana, Slovenia.ORCID 0000-0003-0488-2445

University of Ljubljana · SI

Funding

Slovenian Research Agency J1-2484Slovenian Research Agency P1-0208Slovenian Research Agency Z1-1859

6 · The paper itself

Abstract

Open innovation initiatives provide opportunities for collaboration and sharing of knowledge and experience between industry, academia, and government institutions. Through open innovation, Merck is offering a Mini Library of 80 carefully selected compounds from previous research and development projects to a broader scientific community for testing in academic drug discovery projects. These compounds are predominantly drug-like and cover a broad range of molecular targets. They could potentially interact with other enzymes, receptors, transporters, and ion channels of interest. The Mini Library was tested on seven

Indexed as

Enzyme InhibitorsMonoamine OxidaseAnimalsCholinesterase InhibitorsHumansMiceMonoamine Oxidase InhibitorsResearchStructure-Activity RelationshipCholinesterase InhibitorsEnzyme InhibitorsMonoamine OxidaseMonoamine Oxidase Inhibitorshuman BChEhuman MAO-A/BMerck Mini LibraryMurAMurCmurine AchEscreening

Identifiers

PMID35889355

DOI10.3390/molecules27144484

PMCPMC9320114

OpenAlexW4285394078

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.